These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2840373)

  • 21. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparins: differences and similarities in approved preparations in the United States.
    Bick RL; Fareed J
    Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S63-6. PubMed ID: 10726038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
    Carrie D; Caranobe C; Boneu B
    Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
    Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
    Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
    Shen Y; Kang J
    Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
    Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
    Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins.
    Fareed J; Walenga JM; Hoppensteadt D; Huan X; Racanelli A
    Haemostasis; 1988; 18 Suppl 3():3-15. PubMed ID: 2840372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM; Bara L; Gouin-Thibault I
    Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
    Davidson BL
    Semin Thromb Hemost; 1999; 25 Suppl 3():107-12. PubMed ID: 10549725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
    Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
    Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IIa and anti-Xa plasma activities after subcutaneous low-dose application of low-molecular-weight heparins to rabbits.
    Harbauer G; Kettenring P
    Haemostasis; 1988; 18 Suppl 3():64-8. PubMed ID: 2840376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T
    Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B; Faruel-Bille V; Pierrejean D; Gabaig AM
    Nouv Rev Fr Hematol (1978); 1991; 33(4):287-91. PubMed ID: 1664095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.